SEINE BIO · SCIENCE LIBRARY
ARA-290 / Cibinetide
ARA-290, also called cibinetide, is an erythropoietin-derived research peptide designed without the parent hormone’s red-cell-producing action.
Research compoundA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of ARA-290 / Cibinetide.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Overview
ARA-290, also called cibinetide, is an experimental peptide derived from erythropoietin research. It was designed to investigate tissue-protective signaling without the same blood-cell-production action as conventional erythropoietin. Its identity and clinical development should not be confused with an approved EPO medicine or a general nerve-regeneration product.
Community Use
PeptideDosages.com publishes protocol material for ARA-290. Community interest often focuses on neuropathy and repair. The existence of human research is relevant, but each schedule and claim must be matched to the actual study population, preparation, route, and endpoint.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Week 1: 1 mg for the first two administrations and 2 mg for the third; 2 mg per administration in weeks 2–4. | Weeks 1–2: three times weekly; weeks 3–4: Monday through Friday. | Four weeks active. Break: Four weeks without scheduled doses. | Published informal biohacking claim KirkleyCare |
| Subcutaneous | Daily alternative: 2–5 mg per dose. Separate maintenance alternative: 3 mg per dose. | Daily for the daily alternative; three times weekly for the maintenance alternative. | Daily alternative: 28–30 days. Maintenance alternative: eight weeks. Break: Daily alternative: a break equal to the course length. Maintenance alternative: four weeks. | Published informal biohacking claim PeptaBase |
Important context: The schedules differ substantially. They document informal practice rather than an established optimum or maximum.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
No FDA-approved routine ARA-290 regimen is established. The human research course described below is a study exposure, not an instruction to treat neuropathy. The chart describes a limited research course, not an open-ended treatment duration or a universal maintenance cycle.
Research Findings
A 2014 phase 2 study enrolled adults with type-2 diabetes and painful neuropathy. Participants received a characterized study product at 4 mg daily for 28 days, followed by another month of observation. Reported signals included neuropathic symptoms, metabolic measures, and corneal nerve-fiber findings in a subgroup. These justify further investigation rather than routine prescribing.
U.S. Approval & Access
ARA-290 is not FDA-approved. Human trial participation requires an actual authorized protocol and eligibility process; a research-product listing is not equivalent. A consultation may explain the evidence and options, but it does not guarantee access to cibinetide or enrollment in a trial.
What It Does in the Body
The proposed innate repair receptor pathway differs from the erythropoietin receptor action used to stimulate red-cell production. This supports a research rationale for separating tissue effects from hematopoiesis. It does not establish that every nerve condition shares the same mechanism or that the peptide repairs damage in all patients. For the uses discussed here, reliable clinical onset, peak benefit, and duration are not established. Route-specific human peak exposure and persistence cannot be inferred from community schedules or a laboratory response.
Benefits & Reported Experiences
The trial provides a human signal, but its selected diabetes population and limited observation period restrict generalization. Symptom improvement and a subgroup imaging measure are different outcomes. They should not become a promise of complete nerve regeneration, a predictable response rate, or sustained benefit after a longer unsupervised course.
Side Effects & Risks
The reported absence of identified safety concerns in that study is not a guarantee of long-term safety or freedom from uncommon events. The population, duration, and characterized product matter. A clinician needs to assess the cause of neuropathy and concurrent treatment rather than borrow reassurance for every preparation.
Delivery Options
The studied route and finished preparation form part of the trial’s conditions. They cannot validate every route or product advertised online. This page does not provide injection technique, preparation instructions, or dose conversions; a legitimate research team would supply protocol-specific guidance and monitoring.
Product Quality & Storage
Confirm that a proposal concerns ARA-290/cibinetide rather than conventional erythropoietin or another analog. Matching the actual product to the paper is essential. Quality testing cannot establish clinical effectiveness or replace trial oversight, even when the underlying peptide has a human research history. Storage must follow the authorized finished product’s labeling or an approved study protocol; temperatures and beyond-use times cannot be inferred from research-vial guidance.
Combinations & Interactions
Adding other neuropathy, recovery, or metabolic peptides is a separate question. The cited trial cannot validate a consumer blend or show that several repair mechanisms improve results together. Review concurrent treatments with the clinician; this profile supplies no combination timing or stacking cycle.
Talking With Your Provider
For burning pain, numbness, or another neuropathic symptom, an appointment can focus on identifying the cause and discussing established care. Ask: Which treatment fits my diagnosis? How will improvement be measured? Is a legitimate clinical trial relevant? Education about ARA-290 should support that conversation rather than delay needed assessment.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Recovery & tissue-repair researchEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →